- Home
- TXG vs SUPN Comparison
TXG vs SUPN Comparison
Compare TXG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- SUPN
- Stock Information
- Founded
- TXG 2012
- SUPN 2005
- Country
- TXG United States
- SUPN United States
- Employees
- TXG N/A
- SUPN N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- TXG Industrials
- SUPN Health Care
- Exchange
- TXG Nasdaq
- SUPN Nasdaq
- Market Cap
- TXG 1.7B
- SUPN 2.0B
- IPO Year
- TXG 2019
- SUPN 2012
- Fundamental
- Price
- TXG $13.36
- SUPN $42.69
- Analyst Decision
- TXG Buy
- SUPN Buy
- Analyst Count
- TXG 11
- SUPN 2
- Target Price
- TXG $13.41
- SUPN $41.00
- AVG Volume (30 Days)
- TXG 3.6M
- SUPN 1.1M
- Earning Date
- TXG 08-07-2025
- SUPN 08-05-2025
- Dividend Yield
- TXG N/A
- SUPN N/A
- EPS Growth
- TXG N/A
- SUPN 1411.53
- EPS
- TXG N/A
- SUPN 1.14
- Revenue
- TXG $644,466,000.00
- SUPN $665,125,000.00
- Revenue This Year
- TXG N/A
- SUPN N/A
- Revenue Next Year
- TXG $5.60
- SUPN $15.74
- P/E Ratio
- TXG N/A
- SUPN $37.32
- Revenue Growth
- TXG 2.02
- SUPN 5.55
- 52 Week Low
- TXG $6.78
- SUPN $29.16
- 52 Week High
- TXG $24.76
- SUPN $43.62
- Technical
- Relative Strength Index (RSI)
- TXG 55.08
- SUPN 76.01
- Support Level
- TXG $12.85
- SUPN $40.26
- Resistance Level
- TXG $14.22
- SUPN $42.96
- Average True Range (ATR)
- TXG 0.94
- SUPN 1.78
- MACD
- TXG -0.09
- SUPN 0.54
- Stochastic Oscillator
- TXG 52.02
- SUPN 91.38
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.